Abstract
The major cause of accidental exposure to radioactive iodine that would endanger a sizable population is its release from the core of a functioning nuclear power-generating facility. Because the half-lives of the iodine radionuclides of interest are 8 d or less, an accident at a reactor that has been inactive for a relatively brief period would not create a risk. For similar reasons, it is unlikely that a terrorist act involving a “dirty bomb,” or reactor waste products, would require prophylactic measures to protect the thyroid gland. This discussion applies primarily to large populations exposed to volatile radioiodines, rather than individuals who might be exposed in the setting of a scientific laboratory.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Becker DV, Robbins J, Beebe GW, et al. Childhood thyroid cancer following the Chernobyl accident. Endocrinol Metab Clin North Am 1996; 25:197–211.
Astakhova LN, Anspaugh LR, Beebe GW, et al. Chernobyl-related thyroid cancer in children of Belarus: A case-control study. Radiat Res 1998; 150:349–356.
Naumann J, Wolff J. Iodide prophylaxis in Poland after the Chernobyl reactor accident. Benefits and risks. Am J Med 1993; 94:524–532.
Balonov M, Kaidanovsky G, Zvonova I, et al. Contributions of shortlived radioiodines to thyroid doses received by evacuees from the Chernobyl area estimated using early in vivo activity measurements. Radiat Prot Dosimetry 2003; 105:593–599.
Schneider AB, Robbins J. Ionizing radiation and thyroid cancer. In Fagin JA, editor. Thyroid Cancer. Boston, MA: Kluwer Academic Publishers, 1998:27–47.
Verger P, Aurengo A, Geoffroy B, Le Guen B. Iodine kinetics and effectiveness of stable iodine prophylaxis after intake of radioactive iodine: a review. Thyroid 2001; 11:353–360.
Wolff J. Iodide prophylaxis for reactor accidents. In Nagataki S, Yamashita S, editors. Nagasaki Symposium Radiation and Human Health. Amsterdam: Elsevier Science B.V., 1996:227–237
Takamura N, Hamada A, Yamaguchi N, et al. Urinary iodine kinetics after oral loading of potassium iodine. Endocr J 2003; 50:589–593.
Blum M, Eisenbud M. Reduction of thyroid irradiation from I-131 by potassium iodide. J Am Med Assoc 1967; 200:1036–1040.
Zanzonico PB, Becker DV. Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by I-131 from radioactive fallout. Health Phys 2000; 78:660–667.
Available at: www.fda.gov/cder/drugprepare/KI_Q&A.htm
Available at: www.fda.gov/cder/drugprepare/kiprep
World Health Organization. Guidelines for Iodine Prophylaxis Following Radiation Accidents: Update 1999. Geneva, 1999.
U.S. Food and Drug Administration, Guidance. Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies. 2001.
Chapin DM, Cohen KP, Davis WK, et al. Nuclear safety. Nuclear power plants and their fuel as terrorist targets. Science 2002; 297:1997–1999. (Comment in: Science 2003; 299:201–203.)
Distribution and Administration of Potassium Iodide in the Event of a Nuclear Incident. Washington: The National Academies Press, 2004.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Robbins, J., Schneider, A.B. (2006). Prophylaxis Against Radiation Exposure from Radioiodine. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Humana Press. https://doi.org/10.1007/978-1-59259-995-0_13
Download citation
DOI: https://doi.org/10.1007/978-1-59259-995-0_13
Publisher Name: Humana Press
Print ISBN: 978-1-58829-462-3
Online ISBN: 978-1-59259-995-0
eBook Packages: MedicineMedicine (R0)